RegenxBio and Rocket Signs Exclusive Worldwide License Agreement for NAV AAV9 Vector
Shots:
- RegenxBio to receive $7M upfront- milestones payments plus royalties on net sales. Rocket to get exclusive worldwide rights for RegenxBio’s NAV AAV9 Vector to develop and commercialize gene therapies for Danon disease
- Rocket also has exclusive option to add two additional NAV AAV vectors for Danon disease- for duration of four years
- REGENXBIO's NAV Technology Platform is an adeno-associated virus (AAV) gene delivery system- used for developing gene therapy in multiple therapeutic areas
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
